Dergiler / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 5

Hormone replacement therapy-related changes in the early postmenopausal period (critical window): an in vivo brain proton magnetic resonance spectroscopy study

Sayfa
853–861
Yayın Tarihi
2014-05-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Decreased NAA/Cho and increased Cho/Cr levels do not support the neuroprotective role of HRT in the critical window.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Findings from clinical studies in postmenopausal women with late initiation of hormone replacement therapy (HRT) that test whether HRT protects cognitive functions in women are inconsistent.
📊
Temel Bulgular & Veri:Materials and methods: Proton magnetic resonance spectrometry (1H MRS) was performed in 4 brain regions of 47 healthy postmenopausal women (21 received HRT, 26 did not).
💡
Sonuç & Katkı:Decreased NAA/Cho and increased Cho/Cr levels do not support the neuroprotective role of HRT in the critical window.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Menopause · hormone replacement therapy · critical window

Özet

Findings from clinical studies in postmenopausal women with late initiation of hormone replacement therapy (HRT) that test whether HRT protects cognitive functions in women are inconsistent. The aim of this study was to investigate the effects of HRT on brain metabolite ratios when initiated in the early postmenopausal period (critical window). Materials and methods: Proton magnetic resonance spectrometry (1H MRS) was performed in 4 brain regions of 47 healthy postmenopausal women (21 received HRT, 26 did not). The subjects were aged between 45 and 65 years. The duration of HRT ranged from 1 to 12 years (mean: 6.3 years). The duration of menopause was 2-12 years (mean: 6.1 years) for HRT users and 1-20 years (mean: 7.8 years) for non-HRT users. Metabolite ratios [N-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr] were evaluated. Results: Cho/Cr ratios were significantly increased and NAA/Cho ratios significantly decreased in all 4 regions in the HRT user group compared to the other group after elimination of the effects of age and menopause duration. Regression analysis revealed an association only between NAA/Cho and duration of menopause. Conclusion: HRT-related changes in metabolite ratios are found in all brain regions. Decreased NAA/Cho and increased Cho/Cr levels do not support the neuroprotective role of HRT in the critical window.

Abstract

Findings from clinical studies in postmenopausal women with late initiation of hormone replacement therapy (HRT) that test whether HRT protects cognitive functions in women are inconsistent. The aim of this study was to investigate the effects of HRT on brain metabolite ratios when initiated in the early postmenopausal period (critical window). Materials and methods: Proton magnetic resonance spectrometry (1H MRS) was performed in 4 brain regions of 47 healthy postmenopausal women (21 received HRT, 26 did not). The subjects were aged between 45 and 65 years. The duration of HRT ranged from 1 to 12 years (mean: 6.3 years). The duration of menopause was 2-12 years (mean: 6.1 years) for HRT users and 1-20 years (mean: 7.8 years) for non-HRT users. Metabolite ratios [N-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr] were evaluated. Results: Cho/Cr ratios were significantly increased and NAA/Cho ratios significantly decreased in all 4 regions in the HRT user group compared to the other group after elimination of the effects of age and menopause duration. Regression analysis revealed an association only between NAA/Cho and duration of menopause. Conclusion: HRT-related changes in metabolite ratios are found in all brain regions. Decreased NAA/Cho and increased Cho/Cr levels do not support the neuroprotective role of HRT in the critical window.

🔖

Bu Makaleye Atıf Yap

MAHMUTYAZICIOĞLU, K., BEŞİR, F. H., BARDAKÇI, M. (2014). Hormone replacement therapy-related changes in the early postmenopausal period (critical window): an in vivo brain proton magnetic resonance spectroscopy study. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 5, 853–861. https://ajindex.com/articles/186238

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011; 96: 255–64. Tiidus PM. Benefits of estrogen replacement for skeletal muscle mass and function in post-menopausal females: evidence from human and animal studies. EAJM 2011; 43: 109–14.
  2. Malatyalıoğlu E, Kökçü A, Yanık FF, Alper T. Effects of four different hormone replacement therapy regimens on certain cardiovascular risk factors. Turk J Med Sci 2000; 30: 469–73. Sherwin BB. Hormones, mood and cognitive functioning in postmenopausal woman. Obstet Gynecol 1996; 87: 20–6.
  3. Thakur MK, Sharma PK. Aging of brain: role of estrogen. Neurochem Res 2006; 31: 1389–98.
  4. Pompili A, Arnone B, Gasbarri A. Estrogens and memory in physiological and neuropathological conditions. Psychoneuroendocrinology 2012; 37: 1379–96.
  5. Sherwin BB, Henry JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Front Neuroendocrinol 2008; 29: 88–113.
  6. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62.
  7. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA; 2002: 288: 2170–2. Maki PM. Hormone therapy and cognitive function: is there a critical period for benefit? Neuroscience 2006; 138: 1027–30.
  8. Loucks TL, Berga SL. Does postmenopausal estrogen use confer neuroprotection? Semin Reprod Med 2009; 27: 260–74.
  9. Maki PM, Dumas J. Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. Semin Reprod Med 2009; 27: 250–9.
  10. Mahmutyazıcıoğlu K, Konuk N, Özdemir H, Atasoy N, Atik L, Gündoğdu S. Evaluation of the hippocampus and the anterior cingulate gyrus by proton MR spectroscopy in patients with post-traumatic stress disorder. Diagn Interv Radiol 2005; 11: 125–9. McEwen B. Estrogen action throughout the brain. Recent Prog Horm Res 2002; 57: 357–84.
  11. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007; 72: 381–405.
  12. Low LF, Anstey KJ. Hormone replacement therapy and cognitive performance in postmenopausal women—review by cognitive domain. Neurosci Biobehav Rev 200